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Background: Semiquantitative dipyridamole myocardial perfusion scintigraphy may provide better estimates of periop-
erative cardiac risk than nonquantitative scintigraphy.
Objective: The purpose of this study was to conduct a metaanalysis of semiquantitive dipyridamole myocardial perfusion
scintigraphy for the prediction of perioperative myocardial infarction and cardiac death in patients undergoing
noncardiac vascular surgery.
Methods: The data sources used were MEDLINE (from 1975 to 1999), citation lists, and correspondence with study
authors. We included studies that evaluated preoperative semiquantitative dipyridamole myocardial perfusion scintigra-
phy in patients undergoing noncardiac vascular surgery. For each study, we calculated results on the basis of the
proportion of myocardial segments with reversible perfusion defects. The complications of interest were cardiac death and
nonfatal myocardial infarction. We calculated likelihood ratios (LRs) and areas under the receiver operating characteristic
curves for individual studies and for the combined data.
Data synthesis: We identified nine studies involving a total of 1179 patients with 82 cardiac complications (complication
rate, 7.0%). Most studies were grade C in quality. Normal scans significantly reduced the likelihood of perioperative
cardiac complications (LR, 0.42; 95% CI, 0.20 to 0.88). Fixed defects reduced the likelihood of complications, but the
effect was not statistically significant (LR, 0.51; 95% CI, 0.24 to 1.1). Reversibility in less than 20% of myocardial
segments did not change the likelihood of perioperative cardiac complications (LR, 1.3, 95% CI, 0.88 to 1.9). LRs for
increasing extents of reversibility were: 20% to 29% reversibility (LR, 1.6; 95% CI, 1.0 to 2.6), 30% to 39% reversibility
(LR, 2.9; 95% CI, 1.6 to 5.1), 40% to 49% reversibility (LR, 2.9; 95% CI, 1.4 to 6.2), and 50% or more reversibility (LR,
11; 95% CI, 5.8 to 20). The pooled area under the receiver operating characteristic curve was 0.78 (95% CI, 0.65 to 0.89).
Heterogeneity was found among study results, but exclusion of heterogeneous studies did not significantly change the
summary results.
Conclusion: Reversible defects in less than 20% of myocardial segments do not significantly alter the risk of perioperative
cardiac complications. Greater extents of reversibility on dipyridamole myocardial stress perfusion imaging increase the
risk of perioperative complications after noncardiac vascular surgery, but the quality and amount of data regarding
greater extents of reversibility are limited. (J Vasc Surg 2002;36:534-40.)
Perioperative myocardial infarction occurs in 2% to 15%
of patients undergoing vascular surgery.1 One quarter to
one third of perioperative myocardial infarctions are fa-
tal.2,3 Accurate preoperative assessment of cardiac risk helps
patients and physicians make informed decisions about
surgery, helps physicians choose appropriate methods for
perioperative care, and identifies patients who need more
intensive perioperative monitoring.
Practice guidelines for assessment of perioperative car-
diac risk recommend a clinical assessment followed by
selective use of noninvasive cardiac testing.4,5 The most
extensively studied method of noninvasive cardiac testing is
dipyridamole myocardial stress perfusion imaging. If a re-
versible myocardial perfusion defect is observed during
dipyridamole imaging, then the patient is identified as high
risk for perioperative myocardial infarction and cardiac
death.
This approach is based on the interpretation of myo-
cardial stress perfusion imaging as showing either any re-
versibility or no reversibility of myocardial perfusion de-
fects. However, a semiquantitative description of the extent
of reversibility may result in better prediction of perioper-
ative cardiac complications because the extent of reversibil-
ity is a powerful predictor of the extent of coronary artery
disease on coronary angiography in patients with suspected
coronary artery disease.6 The American College of Cardi-
ology/American Heart Association guideline states that
“the use of techniques to quantitate the extent of abnor-
mality will probably improve the positive predictive nature
of myocardial perfusion imaging.”4 The American College
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of Physicians guideline states that “increased risk discrimi-
nation is obtained from semiquantitative interpretation.”5
Two published metaanalyses of dipyridamole myocar-
dial stress perfusion imaging before vascular surgery have
been published. One study did not address semiquantita-
tive dipyridamole myocardial stress perfusion imaging.7
The other combined three studies8-10 (total of 433 pa-
tients) and found that patients with two or more reversible
defects were more likely to have cardiac complications
(including congestive heart failure and transient myocardial
ischemia) than patients with one or more reversible de-
fects.11 This analysis did not include two early studies that
evaluated 305 patients and report semiquantitative analy-
sis.12,13 Several additional studies of semiquantative dipy-
ridamole myocardial stress perfusion imaging have been
published since 1994. Our objective was to conduct a
systematic review and metaanalysis of evidence about semi-
quantitative dipyridamole-thallium scintigraphy for predic-
tion of nonfatal myocardial infarction and cardiac death
after noncardiac vascular surgery.
METHODS
Assembly of studies
We searched for published and unpublished data with
computerized bibliographies, hand searching of relevant
journals, and correspondence with study authors. In our
MEDLINE search, we used MeSH headings dipyridamole
(exploded) or thallium (exploded), limited to human and
journal article, for the period from 1975 to January 1999.
We also searched with MeSH heading sestamibi (explod-
ed), but no additional articles were identified, so this search
is not reported in detail. We considered reports in all
languages. All article titles, abstracts, and subject headings
were screened for potential relevance. We looked for evi-
dence of preoperative dipyridamole myocardial stress per-
fusion imaging (including thallium-201, technetium-99m
sestamibi, and rubidium-82, and planar, single photon
emission computer tomography, and positron emission
tomography) in the setting of noncardiac vascular surgery,
including carotid endarterectomy, aortic procedures, renal
artery bypass or repair, lower extremity arterial bypass or
thromboendarterectomy, and diabetic amputations. We
excluded articles indexed as a review article or a case report.
We also excluded studies of renal transplantation and vas-
cular access for hemodialysis. The first 300 citations were
screened by two independent reviewers with excellent
agreement regarding potential relevance (simple agree-
ment, 99%; , 0.92), so the remaining citations were
screened by a single reviewer. We also searched the citation
lists of all selected studies and published guidelines to
identify other potentially relevant studies.
Study selection
The full reports of all potentially relevant articles and
abstracts were reviewed in detail for three additional selec-
tion criteria: 1, evidence of semiquantitative interpretation
of scintigraphy results; 2, the reporting of perioperative
myocardial infarction and cardiac death as study outcomes;
and 3, follow-up for at least 1 month or for the duration of
hospitalization. We did not consider unstable angina be-
cause it is not consistently reported, and we did not con-
sider arrhythmias, pulmonary edema, and all-cause mortal-
ity because these are not as strongly related to reversible
cardiac ischemia. When the same data were reported in
more than one article, only the article with the most com-
plete data set was included. A subset of potentially relevant
articles was reviewed by two independent reviewers with
excellent agreement regarding selection (simple agree-
ment, 96%; , 0.90). Authors of studies that met most or all
selection criteria were contacted by mail with a request to
provide methodologic information and additional results.
Evaluation of study methods (Table I)
Two independent reviewers evaluated study methods
according to critical appraisal principles of diagnostic test
research.14 We resolved discrepancies with repeated review
and discussion. We abstracted data on the prospective
enrollment of consecutive participants, with blinded inter-
pretation of scintigraphy and blinded assessment of periop-
erative cardiac complications. We assigned a quality grade
on the basis of these features as previously described.15
Grade A studies involved the independent comparison of
myocardial perfusion scintigraphy results with develop-
ment of perioperative cardiac complications among at least
100 consecutive patients. Grade B studies met the criteria
for grade A studies but had less than 100 patients. Grade C
studies involved nonconsecutive patients or nonindepen-
dent comparisons between the scintigraphy and periopera-
tive cardiac complications.
Several features of perioperative cardiac studies were
considered in our appraisals. First, routine use of dipyrid-
amole myocardial stress perfusion imaging for all patients
before noncardiac vascular surgery is not recommend-
ed.16,17 Accordingly, we determined whether study pa-
tients were selected on the basis of clinical characteristics
indicating increased cardiac risk.
Second, patients with reversible defects may have their
surgery canceled or they may undergo coronary revascular-
ization before noncardiac vascular surgery. In either situa-
tion, these patients are less likely to have a perioperative
cardiac complication, thereby reducing the observed pre-
dictive value of a reversible defect. We determined whether
dipyridamole myocardial stress perfusion imaging results
led to cancellation of surgery or to preoperative coronary
revascularization, and we abstracted data on the clinical and
scintigraphic characteristics of such patients.
Third, patients with reversible defect scans who un-
dergo noncardiac vascular surgery may receive more intense
postoperative electrocardiographic and cardiac enzyme
monitoring. This surveillance bias can result in more diag-
noses of postoperative myocardial infarction in patients
with reversible defects, leading to spuriously high estimates
of sensitivity. Therefore, we assessed the degree of blinding
of caregivers (anesthetists, internists, and surgeons) to di-
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pyridamole myocardial stress perfusion imaging results and
determined whether systematic protocols for postoperative
electrocardiographic and cardiac enzyme monitoring were
used.
Finally, patients with reversible defects may receive
additional perioperative treatments to reduce the likeli-
hood of perioperative cardiac complications. If caregivers
were not blinded to scan results, we abstracted information
on the perioperative care for patients with and without
reversible defects.
Data abstraction
Two independent reviewers abstracted the data. We
resolved discrepancies with repeated review and discus-
sion. Studies quantified the extent of reversibility with
division of the myocardial images into six to 24 segments
and reporting of the number of segments with reversibil-
ity. To standardize results across studies, we calculated
the percentage of myocardial segments showing revers-
ible defects. For example, if the study used a six-segment
Table I. Summary of studies included in metaanalysis
Study
Sample
size
MI/
cardiac
deaths
Patient
characteristics
MI
definition Scintigraphy
Quality
grade Prospective Consecutive
Blinding:
test
Blinding:
outcome
Avoided
surgical
selection
Routine
surveillance
8 237 17 (7%) Diabetes 34%
Angina 18%
MI 30%
CK alone
or with
EKG
Thallium
Planar and
SPECT
Reinjection
C No No Yes No No No
9 101 10 (10%) Diabetes 100% EKG and
CK
Thallium
Planar
C Yes No Yes No Yes No
Angina 46%
MI 39%
12 125 13 (10%) Diabetes 24%
Angina 46%
Any two:
EKG,
CK, or
pain
Thallium
Planar
C No Yes Yes No No No
13 180 12 (7%) Diabetes 18% EKG and
CK
Thallium
Planar
C No No Yes Yes No No
Angina 29%
MI 23%
26 72 5 (7%) Diabetes 26% CK with
pain or
EKG
Rubidium
82 PET
C No Yes Yes No No No
Angina 31%
MI 26%
27 134* 12 (9%) Diabetes 13% EKG and
CK
Thallium
SPECT
Reinjection
A Yes Yes Yes Yes Yes Yes†
Angina 23%
MI 29%
28 197 4 (2%) Diabetes 25% EKG and
CK
Sestamibi
SPECT
C No Yes Yes No No No
Angina 60%
MI 23%
29 104 5 (5%) Diabetes 26% EKG and
CK
Thallium
SPECT
C No Yes Yes Yes No No
Angina 11%
MI 7%
30 29 4 (14%) Diabetes 3% EKG and
CK
Sestamibi
Planar
B Yes Yes Yes Yes Yes Yes‡
Angina 14%
Total 1179 82 (7.0%)
*This study used explicit selection criteria (any two of: age 70 years, history of myocardial infarction, history of congestive heart failure, history of angina,
diabetes mellitus, hypertension with left ventricular hypertrophy, Q waves, or ischemic ST segment changes on baseline electrocardiogram). Of 514 patients
considered for surgery, 134 had at least two of these risk factors, 23 surgeries were canceled for noncardiac reasons, 37 were canceled because of high cardiac
risk, and 317 had less than two risk factors and underwent surgery without scanning. Cardiac events were observed in 11 of 314 patients (3.5%) with less than
two risk factors who did not have scintigraphy.
†Routine surveillance: electrocardiogram and cardiac enzymes every 24 hours for 2 days after surgery.
‡Routine surveillance: electrocardiogram twice daily in intensive care unit (at least 24 hours after surgery) and cardiac enzymes twice daily for 3 days after
surgery.
MI definition: This column describes whether electrocardiographic changes, cardiac enzyme changes, or both are necessary for diagnosis of perioperative
myocardial infarction. Some studies also included clinical criterion of prolonged typical ischemic chest pain.
Blinding: test: Dipyridamole myocardial perfusion scintigraphy was interpreted without knowledge of patient’s perioperative outcome.
Blinding: outcome: Assessment of cardiac complication was made without knowledge of patient’s preoperative dipyridamole myocardial perfusion scintigraphy.
Avoided surgical selection: Surgery was not canceled and patients did not undergo revascularization before noncardiac surgery because of reversible defects
noted on dipyridamole myocardial perfusion scintigraphy. If study did not avoid surgical selection, study would be less likely to show relationship between
reversible defects and perioperative cardiac complications.
Routine surveillance: Standard protocol was used for monitoring all patients after surgery, including electrocardiogram and cardiac enzyme measurement,
regardless of preoperative scan result.
MI, Myocardial infarction; CK, cardiac enzyme; EKG, electrocardiogram; SPECT, single photon emission computed tomography; PET, position emission
tomography.
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model, then reversibility in one segment would corre-
spond to 17% of myocardium showing reversibility.
We recorded study definitions of myocardial infarction,
including electrocardiographic and cardiac enzyme criteria.
Troponin I was not used in any studies. We did not record
data on other cardiac complications, such as unstable an-
gina, pulmonary edema, or arrhythmias.
For each study, we identified patients who had coro-
nary revascularization after scanning but before noncardiac
vascular surgery. Whenever possible, we excluded these
patients from our calculations of diagnostic accuracy. In-
clusion of these patients would spuriously lower the speci-
ficity of an abnormal dipyridamole myocardial stress perfu-
sion imaging result because perioperative cardiac
complications are rare after successful myocardial revascu-
larization.
Data analysis
Individual studies. We calculated nonparametric ar-
eas under the receiver operating characteristic (ROC) curve
for each study with the method of Hanley and McNeil18
and compared the areas under each curve with z tests. We
also calculated binormal estimates for the areas under the
ROC curve, with ROCFIT software19 and a maximum
likelihood method.20,21 A perfect test has an area under the
ROC curve of 1. An area under the curve of 0.5 indicates a
useless test that performs no better than a coin flip.
Combining studies. To determine which studies
could be meaningfully combined, we applied standard prin-
ciples of metaanalysis.22 First, we tried to assemble studies
with reasonably similar features, including patient popula-
tion, type of surgery, type of imaging, and definition of
postoperative myocardial infarction. Second, we assessed
the methodologic quality of each study. Third, we deter-
mined similarity of results amongst the studies by compar-
ing the areas under the ROC curves. With the BUGS23
software, we fitted a Bayesian hierarchic model24 to com-
bine the binormal ROC curve estimates from individual
studies.
We then estimated summary likelihood ratios (LRs) for
increasing extents of reversibility with the Bayesian hierar-
chic model. In advance, we defined seven scan results,
including normal scans, fixed defects only, reversible de-
fects in less than 20%, and reversible defects in 20% to 29%,
30% to 39%, 40% to 49%, and more than 50% of myocardial
segments. The major analytic issue in estimating summary
LRs was that individual studies used different intervals for
reporting extents of reversibility. To calculate the desired
LRs, we interpolated the results from each study to con-
form to the scan results listed previously. These interpola-
tions had little effect on the shape or area of the original or
summary ROC curves.
Once the data had been interpolated to the intervals
listed previously, we calculated stratum-specific LRs for
each study, adding 0.5 to each cell to give the estimate
better properties in the presence of small counts. We used
the DerSimonian and Laird25 random effects method to
obtain a summary LR for each stratum. The summary LRs
were used to convert pretest probabilities of myocardial
infarction to posttest probabilities for test outcomes at each
level of reversibility. A LR of less than 1 reduces the
likelihood of complications, and a LR of less than 0.4
means that the likelihood of complications is substantially
reduced. A LR of greater than 1 increases the likelihood of
complications, and a LR of 4 means that the likelihood of
complications is substantially increased.
RESULTS
We screened 3160 MEDLINE citations, identified 88
potentially relevant articles, and selected 16 for inclusion in
this metaanalysis. The 72 other potentially relevant articles
were excluded for the following reasons: no semiquantita-
tive analysis (n 28), nonvascular surgery (n 10), review
article (n  7), repeat publication (n  7), no myocardial
stress perfusion imaging (n  6), no surgery (n  4),
heterogeneous outcomes (n  3), sample size less than 10
patients (n  2), and other reasons (n  5).(A list of the
excluded articles is available from the corresponding au-
thor). Of the 16 selected articles, we were able to obtain
sufficient data to analyze nine studies.8,9,12,13,26-30 The
remaining seven selected articles did not have enough
information to be included in the metaanalysis, and we
were unable to obtain additional information from the
authors.17,31-36
Methodologic features of primary studies (Table I).
One selected study had a quality grade A,27 another grade
B,30 and the rest were grade C.8,9,12,13,26,28,29 All studies
selected patients for myocardial stress perfusion imaging on
the basis of a clinical suspicion of increased cardiac risk, but
only one study27 explicitly described the selection criteria.
Six studies were partly confounded by cancellation of sur-
gery or revascularization because of abnormal scan re-
sults.8,12,13,26,28,29 In most cases, revascularization or can-
cellation occurred in patients with greater extents of
reversibility.
Caregivers (anesthetists, surgeons, and internists) were
blinded to scintigraphy results in only two studies.27,30 The
remaining studies provided little detail regarding additional
treatments for patients with reversible defects. One study
stated that patients with reversible defects tended to receive
more invasive hemodynamic monitoring and intravenous
nitrates,13 and another stated that optimization of antiisch-
emic therapy and intraoperative hemodynamic monitoring
was routinely recommended in patients with reversible
defects.28
All studies used a similar protocol for infusing dipyrid-
amole. The radiopharmaceutical was thallium-201 in six
studies, 8,9,12,13,27,29 technetium-99m sestamibi in two
studies,28,30 and rubidium-82 in one study.26 Five studies
used single photon emission computed tomogra-
phy,8,27,28,29 one used positron emission tomography,26
and three used planar images.9,12,13,30 The method of
describing extent of reversibility was variable, with a range
of five to 24 segments.
Individual study results (Table II). The areas under
the ROC curves were similar for the nonparametric and
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binormal methods, so we report the nonparametric areas
only. Two studies had significantly lower areas under the
ROC curves than the remaining studies.26,28 Each
study26,28 had a high rate of cancellation for patients with
reversible defects (approximately 20% were canceled). One
of these studies included results for seven patients with
reversible defects who had myocardial revascularization
before noncardiac vascular surgery.28 We were unable to
obtain results of this study with these seven patients ex-
cluded. The individual and summary ROC curves can be
viewed in the Fig (online only).
The extent to which these outlying studies are “biased”
estimates of the accuracy of dipyridamole myocardial stress
perfusion imaging is impossible to determine. Therefore,
we performed analyses with and without these two studies.
Combined study results (Table III). The pooled
area under the summary ROC curve was 0.78 (95% CI,
0.65 to 0.89), with the Bayesian hierarchic model to com-
bine the binormal ROC curve area estimates. When the two
outlying studies were excluded, the pooled area under the
ROC curve was 0.82 (95% CI, 0.69 to 0.92). We obtained
similar results when we combined the nonparametric ROC
curve area estimates with the random effects model.
Normal scans significantly reduced the likelihood of
perioperative cardiac complications (summary LR, 0.42;
95% CI, 0.20 to 0.88). Fixed defects reduced the likelihood
of complications, but the effect was not statistically signif-
icant (summary LR, 0.51; 95% CI, 0.24 to 1.1). Reversibil-
ity in less than 20% of myocardial segments did not change
the likelihood of perioperative cardiac complications (LR,
1.3; 95% CI, 0.88 to 1.9). LRs for increasing extents of
reversibility were: 20% to 29% reversibility (LR, 1.6; 95%
CI, 1.0 to 2.6), 30% to 39% reversibility (LR, 2.9; 95% CI,
1.6 to 5.1), 40% to 49% reversibility (LR, 2.9; 95% CI, 1.4
to 6.2), and 50% or more reversibility (LR, 11; 95% CI, 5.8
to 20). When we excluded the two outlying studies, there
were no statistically significant changes in the results. The
only qualitative difference was that the LR for a normal scan
was lower (0.18; 95% CI, 0.07 to 0.49).
Table III shows the posttest probability for various scan
results, assuming a pretest probability of cardiac complica-
tions of 7%. Table III also shows the distribution of various
scan results: 60% of scans were normal or showed fixed
defects, 17% of scans showed reversibility in less than 20%
of myocardial segments, and 23% of scans showed revers-
ibility in 20% or more of myocardial segments.
Potentially relevant studies that could not be ana-
lyzed. Seven potentially relevant studies were not in-
cluded in this analysis because of inadequate information
regarding semiquantitative analysis. Four studies17,32,34,36
(n  823, including 73 cardiac events) had results that
would strengthen our conclusions. Two studies31,33 (n 
324, including 28 cardiac events) had results of uncertain
effect on our conclusions. One study35 (n 174, including
four cardiac events) had results that would potentially
weaken our conclusions. These studies are summarized in
the Appendix (online only).
DISCUSSION
In this metaanalysis, our major finding is that patients
undergoing preoperative semiquantitative dipyridamole
myocardial perfusion scintigraphy who had reversible de-
fects in up to 20% of myocardial segments did not have an
increased risk of perioperative cardiac complications. We
also found that patients with greater extents of reversible
defects were at increasing risk of cardiac complications after
noncardiac vascular surgery.
Two major methodologic issues may affect our conclu-
sions: the methodologic quality of the primary studies and
publication bias. We believe that our major finding is
unaffected by these methodologic issues, but it is possible
that the predictive value of greater extents of reversibility
has been overestimated.
Most studies in this analysis had suboptimal method-
ologic quality. Ideally, we would like to base our recom-
mendations on higher quality primary studies, but no such
studies exist. Instead, we must examine how the methods of
the individual studies may have affected the results of this
analysis.
First, caregivers were blinded to the results of myocar-
dial stress perfusion imaging in only two studies. It is likely
that additional treatments were given to patients with re-
versible perfusion defects, leading to fewer cardiac compli-
cations. However, the lack of blinding reflects what occurs
in usual practice, so we conclude that patients with revers-
ibility in less than 20% of myocardial segments, who receive
appropriate perioperative care, have an average risk of peri-
operative cardiac complications.
Second, unequal surveillance for postoperative myocar-
dial infarction and unblinded interpretation of study out-
comes would tend to overestimate the predictive value of
myocardial stress perfusion imaging. However, our major
finding is not attenuated by these methodologic limitations
because we conclude that lesser extents of reversibility have
limited predictive value. It is possible that the predictive
value of greater extents of reversibility has been overesti-
mated in our analysis.
We made efforts to minimize the possibility of publica-
tion bias by contacting authors for additional unpublished
Table II. Areas under ROC curves for each study
Study
Area under ROC
curve (95% CI)
8* 0.76 (0.65 - 0.86)
9* 0.82 (0.69 - 0.95)
12 0.96 (0.91 - 1.00)
13 0.86 (0.71 - 1.00)
26† 0.46 (0.13 - 0.79)
27 0.84 (0.73 - 0.95)
28† 0.47 (0.16 - 0.78)
29 0.88 (0.78 - 0.97)
30* 0.73 (0.53 - 0.92)
Combined 0.78 (0.65 - 0.89)
Combined, excluding studies 26 and 28 0.82 (0.69 - 0.92)
*Differs from study 12, P  .05.
†Differs from studies 9, 12, 13, 21, 23, P  .05.
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data. We obtained unpublished data for four of the studies
included in this analysis. We also summarized studies that
could not be included because of incomplete information,
and most of these studies would likely have strengthened
our main conclusion. We believe it is unlikely that we
overlooked studies of any size with results showing a strong
relationship between scintigraphy results and cardiac
events.
We believe that clinicians can use these results to refine
their perioperative risk estimates. Reversible defects in up to
20% of myocardial segments did not significantly alter the
likelihood of cardiac complications. For most patients with
this scan result, it will be reasonable to proceed with sur-
gery, after prescribing -blocker therapy37 where appropri-
ate. Patients with greater extents of reversibility are at
significantly increased risk. Delay or cancellation of surgery,
invasive cardiac testing and revascularization, or -blocker
therapy may be appropriate depending on the clinical cir-
cumstances. Only 23% of scans showed reversibility in more
than 20% of myocardial segments, so the yield of preoper-
ative scintigraphy is low even in selected patients.
The extent of reversibility is not the only relevant
information from preoperative dipyridamole myocardial
stress perfusion imaging. The severity of reversibility within
each defect6,38 and the location of the defect33 are also
important considerations. Other findings, such as transient
left ventricular cavitary dilatation38 or electrocardiographic
changes during dipyridamole infusion,39 may also indicate
increased risk of perioperative cardiac complications. These
variables were not evaluated in this metaanalysis because
they were not routinely reported in the primary studies.
In summary, we conclude that reversible defects in less
than 20% of myocardial segments do not significantly alter
the risk of perioperative cardiac complications. Most of the
studies were unblinded, so patients with reversible defects
in less than 20% of myocardial segments may have received
additional treatments that lowered their risk. Greater ex-
tents of reversibility on dipyridamole myocardial stress per-
fusion imaging increase the risk of perioperative complica-
tions after noncardiac vascular surgery, but the quality and
amount of data regarding greater extents of reversibility are
limited.
We thank the primary authors who supplied us with
additional methodologic information and data from their
studies.
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Online only. ROC curves for individual studies (dashed lines) and combined ROC curve (solid line). Two studies had
significantly lower areas under ROC curve. Analysis was repeated after exclusion of these two studies.
Appendix, online only. Main results of potentially relevant studies that could not be included
Study Sample size
MI/cardiac
death Main result
Probable impact on
conclusion of metaanalysis
17 457 42 (11%)* Thallium reversibility did not
predict postoperative cardiac
complication. Likelihood
ratio for any reversible defect
was 0.94 (95% CI, 0.60 –
1.5).
Strengthen
32 87 10 (11%) Mean proportion of reversible
defects was 7% in patients
without events and 14% in
patients with events.
Strengthen
34 172 16 (9%) ‘Strongly positive’ scans had
likelihood ratio 3.4 (95% CI,
1.5 – 6.9), and ‘weakly
positive’ scans had likelihood
ratio 1.0 (95% CI, 0.4 –
2.2).
Strengthen
36 107 5 (5%) Likelihood ratio for any
reversibility was 1.2 (95%, CI
0.4 – 1.9).
Strengthen
31 231 19 (8.2%) Number of transient defects
was predictive of outcome.
Uncertain
33 93 9 (9.7%) Total number of defects
(transient and fixed) was
highly predictive of
outcome.
Uncertain
35 174 4 (2%) Likelihood ratio for reversibility
in 1/12 segments was
3.3 (95% CI, 0.6 – 12).
Weaken
Total 1321 105 (8%)
*Study did not distinguish between cardiac and noncardiac deaths.
MI, Myocardial infarction.
